被忽视的丁型肝炎  

Neglected hepatitis D

作　　者：庄辉 Zhuang Hui(Department of Microbiology&Infectious Disease Center,School of Basic Medical Sciences,Peking University Health Science Center,Beijing 100191,China)

机构地区：[1]北京大学医学部基础医学院病原生物学系暨感染病中心,北京100191

出　　处：《中华检验医学杂志》2024年第3期205-209,共5页Chinese Journal of Laboratory Medicine

摘　　要：丁型肝炎病毒(HDV)是一种有缺陷病毒, 需要乙型肝炎表面抗原(HBsAg)才能复制。HDV感染呈世界性流行, 但全球不同区域的HDV感染人数不一, 目前尚无丁型肝炎确切的全球流行率数据。我国属于抗-HDV低度流行地区, 然而内蒙古自治区和新疆维吾尔自治区抗-HDV阳性率较高。与HBV单独感染比较, 慢性HBV/HDV重叠感染会更快、更易进展为肝硬化、肝失代偿和肝细胞癌。抗HBV核苷酸类似物(NAs)对控制HDV感染无效, 新批准药物布尔韦肽(BLV)治疗慢性丁型肝炎有较好的安全性和有效性, 目前也未发现耐药突变。Hepatitis D virus(HDV)is a defective virus that requires hepatitis B surface antigen(HBsAg)to replicate.HDV infection is prevalent worldwide,but the number of HDV infections varies in different regions of the world,and there is no exact global prevalence data for hepatitis D.China belongs to an area with low prevalence of anti-HDV.However,the positive rates of anti-HDV are relatively high in Inner Mongolia Autonomous Region and Xinjiang Uygur Autonomous Region.compared to HBV monoinfection chronic HBV/HDV coinfection progresses more rapidly and frequently to cirrhosis,liver decompensation and hepatocellular carcinoma.Anti-HBV nucleotide analogues(NAs)that inhibit HBV replication are ineffective in controlling HDV infection.The newly approved drug Burweipeptide(BLV)has demonstrated good safety and efficacy in the treatment of chronic hepatitis D,and no drug-resistant mutations have been found so far.

关 键 词：肝炎 丁型 慢性丁型肝炎 流行病学 自然史 诊断 治疗 

分 类 号：R512.64[医药卫生—内科学]